UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044400
Receipt number R000050542
Scientific Title Registry of female precocious puberty, aiming identification of predisposing factors, optimization of treatment strategy, and elucidation of prognosis
Date of disclosure of the study information 2021/06/03
Last modified on 2022/06/04 16:16:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Registry of female precocious puberty, aiming identification of predisposing factors, optimization of treatment strategy, and elucidation of prognosis

Acronym

Precocious puberty registry

Scientific Title

Registry of female precocious puberty, aiming identification of predisposing factors, optimization of treatment strategy, and elucidation of prognosis

Scientific Title:Acronym

Precocious puberty registry

Region

Japan


Condition

Condition

female central precocious puberty

Classification by specialty

Endocrinology and Metabolism Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Prospective patient registry, for girls with central precocious puberty, will be constructed.

Basic objectives2

Others

Basic objectives -Others

This study will register prospectively the consecutive female patients with central precocious puberty evaluated at Showa University Hospital. Data obtained from a large number of patients will contribute to reveal the predisposing factors. Analysis of long-term treatment will be useful to develop clinical guideline in future.

Trial characteristics_1

Others

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

1) Information collected at the time of diagnosis: family history, maternal information during pregnancy, perinatal history, past history, social history, growth data, physical findings, endocrine test (LH, FSH, E2, DHEA-S, TSH, Free T3, Free T4, IGF-1), Bone age, ultrasonic findings of uterus and ovary, MRI findings in hypothalamo-pituitary region
2) Information collected during follow-up or treatment
For non-treatment patients: growth data, physical findings, bone age (every 6 months to 1 year until menarche)
For patients with LHRH analog treatment: growth data, physical findings, endocrine test, bone age, ultrasonic findings, treatment details
3) Information to be collected after the completion of treatment
growth data, physical findings, endocrine tests, ultrasonography (6-months and one year following the cessation)

Key secondary outcomes

Serum will be cryopreserved for each patient.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

1 years-old <=

Age-upper limit

12 years-old >=

Gender

Female

Key inclusion criteria

Female patients who will be diagnosed with central precocious puberty (gonadotropin-dependent precocious puberty) at Department of Pediatrics, Showa University Hospital after July 2021.

Key exclusion criteria

1) premature thelarche
2) central precocious puberty with organic origin
3) gonadotropin-independent precocious puberty

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Masanori
Middle name
Last name Adachi

Organization

Showa University School of Medicine

Division name

Department of Pediatrics

Zip code

142-8666

Address

Hatanodai 1-5-8, Shinagawa-ku, Tokyo

TEL

03-3784-8565

Email

m0adachi@med.showa-u.ac.jp


Public contact

Name of contact person

1st name Masanori
Middle name
Last name Adachi

Organization

Showa University School of Medicine

Division name

Department of Pediatrics

Zip code

142-8666

Address

Hatanodai 1-5-8, Shinagawa-ku, Tokyo

TEL

03-3784-8565

Homepage URL


Email

m0adachi@med.showa-u.ac.jp


Sponsor or person

Institute

Showa University

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

SURAC, Showa University

Address

Hatanodai 1-5-8, Shinagawa-ku, Tokyo

Tel

03-3784-8129

Email

m-rinri@ofc.showa-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 06 Month 03 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2021 Year 05 Month 12 Day

Date of IRB

2021 Year 05 Month 12 Day

Anticipated trial start date

2021 Year 07 Month 01 Day

Last follow-up date

2030 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

The observation period is as follows.
1) In the case of untreated follow-up, observation will be continued until menarche.
2) For cases treated with LHRH analog, observation will be continued 12 months after the end of treatment or until (re)start of menstruation.


Management information

Registered date

2021 Year 06 Month 02 Day

Last modified on

2022 Year 06 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050542


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name